麗宝新薬

いまだ満たされていない臨床市場における医療ニーズに対応する新たな医薬品の開発に尽力すべく、2017年1月に当社は設立されました。Libo Pharma Corp.の運営モデルでは、統合モジュール型の共同開発を採用しています。企業本体を管理および核となる能力を発展させる中枢と位置づけ、外部の協力パートナーとの連携により迅速なイノベーション活動を行うとともに、運営時期の各段階において「外部リソース委託／協力モデル」「ライセンスモデル」および「協力連携モデル」を採用し、高度な連携によって、リスクの分散、資金流動の活性化技術開発障壁の引き下げが行われています。
  • 成熟・安定期における新型医薬品の開発ケース
  • 腫瘍医学における併用療法分野での国際的にホットな投資先
  • 変動費を固定費に切り換えることで、資金運用上の柔軟性を拡大
  • ライセンス契約に基づいて導入・導出を行う流水式永続経営のビジネスモデルにより、実現可能な市場価値を速いスピードで創出
  • 国際的戦略における連携体制

Business Model

Dr. Henry Liu is the co-founder and the CEO of Libo Pharma Corp., and shoulders the responsibility of leading, guiding, and overseeing the entire operation, growth and development of the company. Before appointed to be the CEO, Dr. Liu served as Vice President of Libo from 2017 to 2020.

Prior to leading the corporate spin-off of Libo Pharma Corp. from its parent company, Lihpao Life Sciences Corp. (LLSC) in 2017, Dr. Liu worked as an Executive Specialist for the General Manager at LLSC and assumed a wide variety of responsibilities: he directed and supervised several collaborative Next Generation Sequencing research projects in collaboration with clinical oncologists for developing companion diagnostics kits; established and managed international business relations and collaborations.

Dr. Liu received his BSc and MSc in Bioengineering from UC Berkeley and UC San Diego, respectively. He is also an active member of Taiwan Joint Commission of Precision Medicine.

– Henry Liu, Chief Executive Officer

Mandy M.-N. Lee co-founded Libo Pharma Corp. (Libo) with Dr. Henry Liu in 2017, and was named Director of Business Development & Licensing in 2019 . She is responsible for the company’s business development activities, including strategic planning, product portfolio and IP management, in/out-licensing evaluation, technology transfer oversight, and strategic alliance management .

Mandy M.-N. Lee earned her MSc. in Biological Sciences and Technology from National Chiao Tung University, where she is also a PhD candidate. In addition, she received intensive training in business and IP management from Foster school of Business executive education Multi-discipline management of technology program (University of Washington) , and the Europe IPRs programs in Munich (BOEHMERT & BOEHMERT law firm)

– Mandy Lee, Director of Business Development

Mr.Tsai has more than 13 years of experience in vaccine and biologic development and commercialization. Before taking on his current role, he spent 12 years at Merck Sharp and Dohme (MSD), serving in several research & development, technology, and manufacturing roles with increasing scope of responsibilities.

Mr.Tsai was Director of Global Vaccine Technical Operations at MSD from 2019-2021, during which he was responsible for the delivery of a brand-new vaccine commercial manufacturing asset and process. Prior to that, he led process development and commercialization teams supporting pipeline vaccine programs at MSD. He oversaw end-to-end programs starting from early/late-stage process development to commercial manufacturing and licensures (BLA/NDA).

Before joining the industry, Mr.Tsai obtained his Master Degree from University of Pennsylvania and a B.A degree from University of British Columbia.

– Peter Tsai, Head of Strategy & Alliance